Pityriasis rosea may be a weak infectious disease, and it is currently thought that it may be associated with human herpesvirus HHV-7 and HHV-6 infection. Person to person transmission has not been confirmed, but there are clusters of morbidity phenomenon, occasionally family, school, military barracks and other close contacts at the same time or successive morbidity phenomenon. It affects mostly young and middle-aged people and is more common in spring and autumn. The initial lesions are isolated rose-colored pale red spots, then the lesions can rapidly expand to 2-3 cm in diameter, with clear borders and covered with fine scales, called prodromal spots or mother spots, often occurring on the trunk and proximal extremities. 1-2 weeks later, pale red rashes appear one after another, about the size of the nail cap, generally less than 2.0 cm in diameter, often oval, with thin scales covered with circled free edges inward, and the long axis parallel to the skin lines. The rash is usually distributed on the neck, trunk, and proximal extremities. It is often accompanied by varying degrees of pruritus. The duration of the disease is usually 6-8 weeks, but there are cases that do not heal for several months or even years, but it usually does not recur after healing. The main purpose of treatment is to reduce symptoms and shorten the course of the disease. Oral antihistamines can be given to those with severe or prolonged disease, and oral glucocorticoids can be given in small doses for a short period of time as appropriate. UVB radiation, i.e. ultraviolet light, can improve clinical symptoms.